CIK 0001515673 · Large accelerated filer
Ultragenyx Pharmaceutical Inc.
Sign in to watch- Ticker
- RARE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 272546083
- Phone
- 415-483-8800
- Business address
- 60 LEVERONI COURT, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $127,561
- in 3 filings, $17K under 10b5-1 plans
Net −$127,561. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-01 | Kassberg Thomas Richard CBO & EVP | Grant or award | +18,443 | 271,266 | ||
| 2025-03-01 | Parschauer Karah Herdman EVP and Chief Legal Officer | Grant or award | +18,443 | 88,133 | ||
| 2025-03-01 | Crombez Eric EVP and Chief Medical Officer | Grant or award | +16,813 | 65,244 | ||
| 2025-03-01 | Crombez Eric EVP and Chief Medical Officer | Grant or award | +14,971 | 80,215 | ||
| 2025-03-01 | Crombez Eric EVP and Chief Medical Officer | Grant or award · Stock Ooption (Right to Buy) | +30,246 | 30,246 | ||
| 2025-03-01 | Pinion John Richard See Remarks | Grant or award | +14,494 | 103,762 | ||
| 2025-03-01 | Pinion John Richard See Remarks | Grant or award | +18,443 | 122,205 | ||
| 2025-03-01 | Pinion John Richard See Remarks | Grant or award · Stock Option (Right to Buy) | +26,074 | 26,074 | ||
| 2025-03-01 | KAKKIS EMIL D President & CEO | Grant or award 10b5-1 | +43,268 | 607,873 | ||
| 2025-03-01 | KAKKIS EMIL D President & CEO | Grant or award 10b5-1 | +107,292 | 715,165 | ||
| 2025-03-01 | KAKKIS EMIL D President & CEO | Grant or award · Stock Option (Right to Buy) 10b5-1 | +78,448 | 78,448 | ||
| 2025-03-01 | Harris Erik EVP & Chief Commercial Officer | Grant or award | +16,813 | 83,976 | ||
| 2025-03-01 | Harris Erik EVP & Chief Commercial Officer | Grant or award | +18,443 | 102,419 | ||
| 2025-03-01 | Harris Erik EVP & Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +30,246 | 30,246 | ||
| 2025-03-01 | Huang Dennis Karl See Remarks | Grant or award | +14,494 | 97,496 | ||
| 2025-03-01 | Huang Dennis Karl See Remarks | Grant or award | +18,443 | 115,939 | ||
| 2025-03-01 | Huang Dennis Karl See Remarks | Grant or award · Stock Option (Right to Buy) | +26,074 | 26,074 | ||
| 2025-03-01 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Grant or award | +9,392 | 51,232 | ||
| 2025-03-01 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +5,632 | 5,632 | ||
| 2025-03-01 | Horn Howard Chief Financial Officer | Grant or award | +15,653 | 107,954 |
Page 6 of 11 · 204 trades